Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Up 87.5% in June

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) saw a significant growth in short interest in June. As of June 15th, there was short interest totaling 73,164 shares, a growth of 87.5% from the May 31st total of 39,018 shares. Currently, 10.5% of the shares of the company are short sold. Based on an average daily volume of 362,400 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Price Performance

LABT remained flat at $2.75 during trading on Friday. 669,278 shares of the company traded hands, compared to its average volume of 298,971. The stock has a 50-day simple moving average of $12.68. Lakewood-Amedex Biotherapeutics has a 52 week low of $2.61 and a 52 week high of $98.20.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.